A. Chevigne

Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma

This study shows that targeting ACKR2 enhances anti-PD-1 immunotherapy efficacy in melanoma by improving the tumor microenvironment and immune cell infiltration.

Design, synthesis and pharmacological characterization of the first photoswitchable small-molecule agonist for the Atypical Chemokine Receptor 3

This paper designs and characterizes the first photoswitchable small-molecule agonist for ACKR3, showing its selectivity and light-controlled activation properties.

Molecular basis of ligand promiscuity, structural mimicry, and atypical dimerization in the chemokine receptors

This study investigates ligand promiscuity and signaling bias in chemokine receptors by analyzing binding modes and determining cryo-EM structures of receptor-ligand complexes.

Pharmacological characterization and radiolabeling ofVUF15485, a high-affinity small-molecule agonist for theatypical chemokine receptor ACKR3

This paper characterizes VUF15485, a high-affinity ACKR3 agonist, and reports its radiolabeling and binding properties.

Computationally designed GPCR quaternary structures bias signaling pathway activation

The paper designs GPCR quaternary structures to bias signaling pathway activation and identifies a conformational switch controlling G protein vs β-arrestin recruitment.

CXCR4-binding PET tracers link monocyte recruitment and endothelial injury in murine atherosclerosis

This study shows that a CXCR4-binding PET tracer accumulates in atherosclerotic plaques due to endothelial CXCR4 expression, linking endothelial injury to monocyte recruitment.